ArticleHealth science reports2026
Current Trends in NSAID Prescribing for Osteoarthritis and Axial Spondyloarthritis: Insights From Moroccan Rheumatologists Practices.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Nonsteroidal anti-inflammatory drugs (NSAIDs) remain the cornerstone of symptomatic management in osteoarthritis (OA) and axial spondyloarthritis (axial SpA), but safety concerns have reshaped prescribing behaviors. This study aimed to describe current NSAID prescribing practices among Moroccan rheumatologists for both conditions. Methods: A cross-sectional descriptive survey was conducted among rheumatologists from public and private sectors. Data were collected using a 30-item validated questionnaire approved by an expert committee. Results: Eighty-two rheumatologists participated. More than half (56.1%) reported having no absolute age limit for NSAID use, while 24% avoided NSAIDs in patients aged > 75 years. The most concerning combination was NSAIDs with vitamin K antagonists (96.3%), and the most cited contraindication was active gastroduodenal ulcer (85.4%). Only 13.4% routinely requested renal function tests before prescribing NSAIDs. Proton pump inhibitors were co-prescribed mainly for a history of gastrointestinal bleeding (93.9% with conventional NSAIDs; 87.8% with coxibs). Naproxen (95.1%), celecoxib (63.4%), and meloxicam (58.5%) were considered the safest for cardiovascular risk. Celecoxib was the first-line NSAID for OA (47.6%), while diclofenac was preferred for axial SpA (34.9%) and celecoxib in patients with inflammatory bowel disease (73.2%). Nearly half (47.6%) prescribed NSAIDs on an as-needed basis. Conclusion: NSAID prescribing in OA and axial SpA is increasingly personalized, with choices guided by comorbidities and safety concerns. Celecoxib is preferred for OA, while diclofenac remains first-line for axial SpA, with caution in patients at gastrointestinal or cardiovascular risk.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.